New drug AZD4916 put to the test in healthy people first
NCT ID NCT06951880
First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times
Summary
This early-stage study tests whether the experimental drug AZD4916 is safe and how it moves through the body in 160 healthy adults, including Japanese and Chinese volunteers. Participants receive either the drug or a placebo, and researchers monitor for side effects. This study does not aim to treat any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 160 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Main Inclusion Criteria: * Healthy male and female participants with suitable veins for cannulation or repeated venipuncture. * All females must have negative pregnancy test and females of childbearing potential must not be lactating and must agree to use an approved method of highly effective contraception. * Have a Body Mass Index between 18 and 30 kg/m2 inclusive and weigh at least 45 kg at Screening. * Part 2, Japanese participants only: Japanese participants must have been born in Japan, have 2 Japanese biological parents and 4 Japanese grandparents (as confirmed by the interview), and must not have lived outside of Japan for more than 10 years at the time of the Screening Visit. * Part 2, Chinese participants only: Chinese participants must have been born in China (including Hong Kong, Macau, and Taiwan), have 2 Chinese biological parents and 4 Chinese grandparents (as confirmed by the interview), and must not have lived outside of China for more than 10 years at the time of the Screening Visit. Main Exclusion Criteria: * History of any clinically important disease or disorder which, in the opinion of the Principal Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * History of chest irradiation, fibrosis, malignancy, surgical procedure, trauma or liver disease. * Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results. * Evidence of active tuberculosis or Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection. * Abnormal vital signs or clinically important abnormalities in rhythm. * Current smokers, known or suspected history of alcohol, drug abuse or caffeine intake. * History of severe allergy/hypersensitivity. * Plasma donation within 1 month of the Screening Visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the Screening Visit. * Participants who are vegans or have dietary restrictions. * Vulnerable participants, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Research Site
RECRUITINGGlendale, California, 91206, United States
-
Research Site
WITHDRAWNHarrow, HA1 3UJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body
- Radioactive tag lets scientists follow an experimental drug through the human body